| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
I evaluated the usefulness of rasH2 with human c-Ha-ras proto-oncogene as the animal model of muscle-invasive bladder cancer. I administered 0.05% BBN for 20 weeks. Although there are no significant differences in the incidence of all bladder cancer, as far as the incidence of bladder invasive cancer is concerned, rasH2 has the higher frequency compared with WT. The mean survival time of rasH2(23.3 weeks) was significantly shorter compared with WT(24.3 weeks). Consequently, rasH2 is a high susceptibility to bladder chemical carcinogenesis with the use of BBN. In particular, this study indicated the usefulness of rasH2 as model animals of invasive bladder cancer.
|
